Ads
related to: b-cell lymphoma of the spleen definition and treatment diagnosis- Dosing Information
View The Dosing Schedule
And Administration Information
- Request More Information
Got Questions? Visit Our Website
And Request More Information
- Hear From An Expert
Hear From A HCP On This Treatments
Dosing, Safety Profile, And More
- Video Library
Watch A HCP Talk About
Dosing, Safety Profile, And More
- Patient Support
Find Patient Support Info Including
Coverage & Financial Support
- Mechanism Of Action
Visit Our Website & Learn About
The Mechanism Of Action
- Dosing Information
Search results
Results From The WOW.Com Content Network
DLBCL is an aggressive type of B-cell NHL that grows rapidly in the lymph nodes and frequently involves the spleen, liver, bone marrow or other organs. 4 Although the disease can affect people of ...
The B-cell lymphomas are types of lymphoma affecting B cells. Lymphomas are "blood cancers" in the lymph nodes . They develop more frequently in older adults and in immunocompromised individuals.
Splenic marginal zone lymphoma (SMZL) is a low grade lymphoma in which malignant B-cells accumulate in the spleen, bone marrow, and, less commonly, the circulation. While generally an indolent disease, about 5-10% of cases transform into a far more aggressive malignancy, diffuse large B-cell lymphoma. [64]
Splenic marginal zone lymphoma (SMZL) is a type of marginal zone lymphoma, a cancer made up of B-cells that replace the normal architecture of the white pulp of the spleen. The neoplastic cells are both small lymphocytes and larger, transformed lymphoblasts , and they invade the mantle zone of splenic follicles and erode the marginal zone ...
T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a DLBCL in which tumors containing small numbers of usually large neoplastic B-cells embedded in a background of reactive T-cells and histiocytes develop in the liver, spleen, bone marrow and/or, rarely other sites. Patients usually present with advanced disease; their overall 3 year ...
Four chimeric antigen receptor T cell therapies are FDA-approved for non-Hodgkin lymphoma, including lisocabtagene maraleucel (for relapsed or refractory large B-cell lymphoma with two failed systemic treatments), axicabtagene ciloleucel, tisagenlecleucel (for large B-cell lymphoma), and brexucabtagene autoleucel (for mantle cell lymphoma ...
Ad
related to: b-cell lymphoma of the spleen definition and treatment diagnosis